| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 20 | 20.6x | 17.6x | Bottom tier | |
Growth | 98 | 76.1% | 7.1% | Top tier | |
Quality | 88 | 50.2% | 4.5% | Top tier | |
Safety | 52 | 2.1x | 2.6x | Around median | |
Capital Return | 21 | — | 2.15% | Bottom tier | |
Momentum | 98 | 71.4% | 2.3% | Top tier | |
Sentiment | 45 | 6 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
TG Therapeutics is a biopharmaceutical company commercially focused on BRIUMVI for the treatment of relapsing multiple sclerosis, generating most of its revenue from product sales within the United States, alongside sales to its partner outside the United States and license and royalty revenue. In fiscal Q2 2026, net U.S. BRIUMVI revenue was approximately $228 million, and total product revenue was $236 million, while total revenue rose to $240 million after adding $4.5 million in license, royalty, and other revenue. The company is working to expand the franchise through a simplified intravenous initiation schedule, a self-administered subcutaneous formulation, studies in myasthenia gravis and treatment-resistant schizophrenia, as well as the azer-cel program.
Fiscal Q2 2026 delivered year-over-year growth of more than 64% in net U.S. BRIUMVI revenue, with sequential growth of approximately 17%, and the company recorded a new quarterly high in new patient starts. Gross margin for the U.S. business was approximately 87%, while total gross margin was 83% due to the mix of partner sales outside the United States and other revenue. The company reported operating income of $21.7 million and net income of $7.8 million, or $0.05 per diluted share, after operating expenses of approximately $150 million included about $55 million related to manufacturing for the subcutaneous formulation and the secondary supply source.
Historical financial results reflect the company’s transition to a larger revenue and profitability scale, with fiscal year 2025 revenue of approximately $616.3 million, gross profit of $515.6 million, and net income of $447.2 million. Revenue for the trailing twelve months ended in 2026 was approximately $700.3 million, with gross profit of $581.7 million and net income of $461.9 million. However, reported net income requires careful interpretation when assessing recurring operating strength, because fiscal Q2 2026 results showed that manufacturing expenses and investment in expansion can create a significant difference between underlying profit and reported accounting profit.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus is “Buy,” with an average price target of $80.5 and a narrow range between $78 and $83; the average and all targets are above the 52-week range high of $59.3. No displayed price-to-earnings ratio is available, so the stock’s valuation is based more heavily on BRIUMVI growth expectations and the results of the subcutaneous formulation, while collective optimism must be balanced against the stock’s sensitivity demonstrated on August 3, 2026, when fiscal Q2 2026 earnings per share came in below estimates.
Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.
BRIUMVI is the company’s primary commercial driver and is a treatment for relapsing multiple sclerosis. In fiscal Q2 2026, the product generated approximately $228 million in net U.S. revenue, an increase of more than 64% year over year and approximately 17% sequentially. Total product revenue, including sales to the partner outside the United States, was $236 million out of total revenue of $240 million. The number of patients prescribed BRIUMVI globally also exceeded 30 thousand as of August 3, 2026.
The company raised its guidance for net U.S. BRIUMVI revenue to $890–905 million in fiscal year 2026. Net U.S. revenue during the first half was approximately $423 million, while total revenue reached approximately $445 million. Management expects approximately $950 million in total global revenue in fiscal year 2026. It also aims to exit fiscal Q4 2026 with quarterly net U.S. revenue exceeding $250 million and an annualized rate exceeding $1 billion.
BRIUMVI currently participates in the physician-administered treatment segment, which represents approximately 60%–65% of the anti-CD20 market. Self-administered treatments represent approximately 35%–40% of the dynamic market, a segment in which the product does not currently participate. The subcutaneous formulation showed positive phase 1 bioavailability data, and the fully enrolled phase 3 study is evaluating a quarterly dosing regimen using an autoinjector. The company expects topline study results near the end of 2026 or the beginning of 2027 and believes pricing factors could make the addressable opportunity more than twice the current market for the intravenous product.
In fiscal Q2 2026, TG Therapeutics recorded operating income of $21.7 million and net income of $7.8 million, or $0.05 per diluted share. Operating expenses of approximately $150 million included about $55 million related to manufacturing the subcutaneous formulation and the secondary supply source. Excluding these expenses, the company estimated operating income of approximately $76 million and net income of approximately $62 million. Nevertheless, reported earnings per share came in below analysts’ estimates on August 3, 2026, which overshadowed revenue growth and raised guidance in the market’s reaction.
In fiscal Q2 2026, the company announced positive phase 3 results from the ENHANCE study, supporting initiation of BRIUMVI with a single 600-milligram infusion instead of two doses on day 1 and day 15. Phase 3 results for the subcutaneous formulation are expected near the end of 2026 or the beginning of 2027. The company also initiated a phase 2 study in myasthenia gravis and another in treatment-resistant schizophrenia. Enrollment in the azer-cel program exceeded twenty patients, with the study expanding to relapsing multiple sclerosis, myasthenia gravis, CIDP, and NMO.
The company ended fiscal Q2 2026 with approximately $612 million in cash, cash equivalents, and investment securities. Gross margin for the U.S. BRIUMVI business was approximately 87%, while total gross margin reached 83%. The company expects operating expenses between $350 and $400 million in fiscal year 2026, excluding stock-based compensation, in addition to approximately $100 million in manufacturing expenses. A significant portion of manufacturing activities could represent saleable inventory and future margin support if the related programs succeed.
